Skip to main content

Table 3 Pathways associated with fasting glucose across human and mouse association datasets

From: Mergeomics: multidimensional data integration to identify pathogenic perturbations to biological systems

Pathway

MSEA

Meta-MSEA

Human

Mouse

Mouse

Mouse

GWAS

GWAS

TWAS

EWAS

Value

FDR

Glycolysis/Gluconeogenesis

2.56

0.88

3.84

0.63

4.73

2.22 %

Starch and sucrose metabolism

3.67

1.37

3.29

0.17

4.57

2.22 %

Regulation And Function Of ChREBP in Liver

3.10

0.93

2.74

0.41

4.08

3.60 %

Nuclear Receptors in Lipid Metabolism and Toxicity

5.58

0.48

1.99

0.35

4.00

3.60 %

Regulation of gene expression in beta cells

4.16

1.75

1.48

0.19

3.97

3.60 %

Type II diabetes mellitus

2.11

1.09

1.48

1.08

3.66

6.00 %

Integration of energy metabolism

2.42

0.33

2.17

1.09

3.34

10.82 %

Steroid biosynthesis

1.10

2.04

1.27

0.76

3.10

14.34 %

alpha-linolenic acid (ALA) metabolism

3.40

0.32

1.72

0.69

3.09

14.34 %

Incretin Synthesis, Secretion and Inactivation

3.24

1.14

0.09

2.06

3.02

14.34 %

Adipocytokine signaling pathway

2.55

0.41

1.13

1.26

2.94

14.34 %

Chylomicron-mediated lipid transport

0.43

0.89

2.89

1.26

2.92

14.34 %

Glucose transport

5.57

1.31

0.27

0.29

2.92

14.34 %

  1. The results are listed as − log10 P-values, and the full table is available in Additional file 5. MSEA was run with top 50 % of markers, and an LD cutoff r2 < 50 % was applied to the GWAS. For the human GWAS, SNPs were assigned to genes based on a 20 kb window in the genome sequence. For the mouse GWAS, liver eQTL data were used for gene assignment. The Bonferroni-adjusted 5 % significance level for 1346 independent tests is at − log10P = 4.43